Linker Information

General Information of This Linker

Linker ID	LIN0UQJNN
Linker Name	Amide-based linker
Linker Type	Flexible reactive (amino) linker
Antibody-Linker Relation	Uncleavable
Structure
Structure	3D MOL		2D MOL
Formula	C6H13NO
Isosmiles	CC(C)CCC(N)=O
InChI	InChI=1S/C6H13NO/c1-5(2)3-4-6(7)8/h5H,3-4H2,1-2H3,(H2,7,8)
InChIKey	ACMPWZQOUILVFB-UHFFFAOYSA-N
Pharmaceutical Properties	Molecule Weight	115.176	Polar area	43.09
	Complexity	8	xlogp Value	0.9079
	Heavy Count	8	Rot Bonds	3
	Hbond acc	1	Hbond Donor	1

Each Antibody-drug Conjugate Related to This Linker

Full Information of The Activity Data of The ADC(s) Related to This Linker

CMB-401 [Terminated in phase 2]

ADC Info

Identified from the Human Clinical Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC			[1]
Efficacy Data	Objective Response Rate (ORR)	0.00%
Patients Enrolled	Platinum-sensitive EOC (recurrence >6 months after completion of an initial platinumcontaining chemotherapy regimen).
Administration Dosage	Initial infusion of 35 mg/m² of hCTM01 (anti-PEM antibody not conjugated to calicheamicin) over a period of 15 min, followed 45 min later (60 min from the start of the initial infusion) by an infusion of 16 mg/m² of CMB-401 over an additional 60 min, up to 7 cycles, with 4 weeks between cycles.
Experiment 2 Reporting the Activity Date of This ADC			[2]
Patients Enrolled	EOC refractory to or unsuitable for platinum/standard therapy; with a WHO performance status of 0-2; life expectancy of more than three months and fulfilling other standard eligibility criteria.
Administration Dosage	Up to four cycles of a dual infusion of 35.00 mg/m² hCTMO1 'predose' followed by doses of CMB-401 which were increased for each cohort, CMB-401 dosing commenced at 2 mg/m² and progressed via seven cohorts to 16.00 mg/m².

References

Ref 1	A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma. Cancer Immunol Immunother. 2003 Apr;52(4):243-8.
Ref 2	Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer. Ann Oncol. 2000 Jun;11(6):735-41.